Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic analysis of peripheral blood mononuclear cells (PBMC) in psoriasis patients treated with guselkumab

ABSTRACT: Transcriptomic analysis of peripheral blood mononuclear cells (PBMC) in psoriasis patients treated with guselkumab

PROVIDER: PRJNA831443 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Transcriptomic analysis of peripheral blood mononuclear cells (PBMC) in psoriasis patients treated with guselkumab

Project description:Psoriasis is a worldwide chronic inflammatory skin disease. The treatment is usually designed according to its severity. In this research, RNA-seq was performed on the peripheral blood mononuclear cells (PBMCs) of 12 patients with psoriasis before and after treatment (4 week) of guselkumab.

2022-04-27 | GSE201397 | GEO

Guselkumab (interleukin-23-specific monoclonal antibody) demonstrates clinical and molecular response in moderate-to-severe psoriasis

Project description:A gene expression profiling study was conducted in which skin biopsy samples were collected for RNA extraction and hybridization to microarrays from patients with moderate-to-severe psoriasis who participated in the phase 1, guselkumab first-in-human randomized, double-blind, placebo-controlled trial. At week 12, significant reductions in psoriasis gene expression were observed in guselkumab-treated patients. Skin biopsy samples (n=59, LS: lesion, NL: non-lesion) were collected at baseline, weeks 1 and 12 following guselkumab treatment from patients with moderate-to-severe psoriasis for RNA extraction and microarray analysis.

2014-05-14 | E-GEOD-51440 | biostudies-arrayexpress

Guselkumab (interleukin-23-specific monoclonal antibody) demonstrates clinical and molecular response in moderate-to-severe psoriasis

2014-05-14 | GSE51440 | GEO

Guselkumab reduces disease- and mechanism-related biomarkers more than adalimumab in patients with psoriasis: a VOYAGE 1 substudy

Project description:In the phase 3 VOYAGE-1 trial (ClinicalTrials.gov identifier: NCT02207231), guselkumab demonstrated superior efficacy versus placebo and the tumor necrosis factor (TNF)-α antagonist, adalimumab, in patients with moderate-to-severe plaque psoriasis (Blauvelt et al., 2017). Here, skin samples were collected from patients in VOYAGE-1 and pharmacodynamic (PD) responses to guselkumab (vs adalimumab) treatment were assessed over 48 weeks.

2024-07-31 | GSE252029 | GEO

Transcription profiling of human peripheral blood mononuclear (PBMC) cells in pulmonary arterial hypertension

Project description:Microarray analysis of peripheral blood mononuclear (PBMC) cells in pulmonary arterial hypertension.

2007-09-21 | E-GEOD-703 | biostudies-arrayexpress

Peripheral blood transcriptome profiles derived from parallel venipuncture (PAXgene and mononuclear cell; PBMC) and dried blood spot (DBS) samples.

Project description:Comparison of transcript abundance estimates and bioinformatic inferences derived from DBS vs PAXgene vs peripheral blood mononuclear cell (PBMC) samples.

2016-05-18 | GSE75511 | GEO

Transcriptome profiling of peripheral blood mononuclear cell subsets

Project description:Transcriptome profiling was conducted on 2 replicate samples of total peripheral blood mononuclear cells (PBMC) and isolated PBMC subsets.

2020-04-14 | GSE101489 | GEO

Gene expression changes in Peripheral Blood Mononuclear cells (PBMC) induced by physical activity

Project description:Gene expression changes in Peripheral Blood Mononuclear cells (PBMC) induced by physical activity was investigated in sedentary middle-aged men (mean age 52.6 years and BMI 29.1) who undertook a 24-week physical activity programme with blood sampling in the pre-exercise period , at the end of 24-weeks prescribed physical activity , and following a two-week detraining period. AgilentTM Whole Human Genome Oligo Microarrays were utilised to examine the effects of physical activity on mRNA expression profiles of the Peripheral Blood Mononuclear cells (PBMC) at 3 time points (pre-exercise, after 24 weeks physical activity, and at 26 weeks after 2 weeks detraining. There were 12 participants in this programme.

2010-08-03 | E-GEOD-12385 | biostudies-arrayexpress

Real-time quantitative PCR analysis of human peripheral mononuclear cells (PBMC) [UPR Phenotypes]

Project description:Human peripheral mononuclear cells(PBMC) were purified from control and diseased (Cataract, Classical Pseudoexfoliation(Cl PXF), Pigmentary Pseudoexfoliation(Pig PXF)) volunteers' blood and mRNA was extracted using QIAzol® lysis reagent. complemenatry DNA(cDNA) was prepared and expression was analysed using PCR based arrays. We used QIAGEN online software to quantitate the differential gene expression .

2020-10-27 | GSE135655 | GEO

Real-time quantitative PCR analysis of human peripheral mononuclear cells (PBMC) [Fibrosis Stages]

Project description:Human peripheral mononuclear cells(PBMC) were purified from control and diseased (Pseudoexfoliation (PXF), Ocular Hypertension(OHT), Pseudoexfoliation Glaucoma(PXG)] volunteers' blood and mRNA was extracted using QIAzol® lysis reagent. complemenatry DNA(cDNA) was prepared and expression was analysed using PCR based arrays. We used QIAGEN online software to quantitate the differential gene expression .

2020-10-27 | GSE135654 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data